Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Literacy to Targeted Risk Inquiry

The legacy of general health and science information has long served as a foundation for public understanding of medical risks, emphasizing broad preventive principles and the importance of informed patient care. Within this heritage, the focus has traditionally been on lifestyle factors, nutrition, and common disease prevention, providing a baseline for how individuals engage with their own well-being. As this informational framework evolves, it increasingly accommodates specialized inquiries that arise from clinical observations and patient-reported outcomes. One such area of growing attention involves the relationship between pharmaceutical interventions and rare but serious adverse events. Specifically, the question of whether bisphosphonate therapy, such as Fosamax, is associated with osteonecrosis of the jaw represents a pivot from general health awareness to a more targeted risk assessment. This transition requires examining exposure contexts that extend beyond routine patient education, particularly in settings where cumulative or high-dose usage may occur. The occupational exposure concern emerges when considering healthcare professionals, dental practitioners, and caregivers who may encounter heightened risks through repeated handling or administration of such medications. Thus, the shift from a general health framework to a focused inquiry on Fosamax and jaw health underscores the need for nuanced risk communication that respects both the legacy of broad health literacy and the specificity of exposure scenarios in professional environments.

Understanding Fosamax and Its Association with Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the jaw that can occur spontaneously or following dental procedures. Clinical presentation and diagnosis of ONJ typically involve delayed healing after tooth extraction, local infection, or spontaneous bone exposure. The condition is generally associated with invasive dental procedures such as tooth extraction, dental implants, or boney surgery, as well as local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Known risk factors for ONJ include diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Evidence of Causation

Mechanistic pathways linking Fosamax to ONJ are not fully established, but research suggests that bisphosphonates may alter jawbone-specific responses. A multiscale characterization of jawbone provides information that can help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). This indicates that the unique properties of jawbone may contribute to its susceptibility to ONJ when exposed to bisphosphonates like Fosamax. Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw. It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, in placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as jaw pain or swelling were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a known adverse event, its incidence in clinical trials was not significantly elevated compared to placebo.

Clinical Considerations and Risk Management

Causation-related considerations for affected patients involve evaluating the timeline between exposure and documented harm. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a potential causal relationship, as symptoms can appear after exposure and resolve upon withdrawal, with recurrence upon re-exposure. For patients who develop ONJ while taking Fosamax, the prescribing information advises discontinuation if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may be reduced by discontinuing bisphosphonate treatment prior to invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, evidence indicates that Fosamax is associated with osteonecrosis of the jaw, with a variable onset timeline and identifiable risk factors. The prescribing information includes warnings about this adverse event, and clinical data show symptom resolution upon discontinuation in most cases. Patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis treatment against the potential risk of ONJ, particularly in those with additional risk factors or requiring invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the association between Fosamax and osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate that has been associated with osteonecrosis of the jaw (ONJ), a condition where bone in the jaw becomes exposed and fails to heal. The risk may increase with longer duration of use and is higher in patients with certain risk factors such as cancer, chemotherapy, poor oral hygiene, or invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What are the symptoms and risk factors for ONJ related to Fosamax?

Symptoms include delayed healing after dental procedures, exposed bone, pain, swelling, or infection in the jaw. Risk factors include cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures, and longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is the causal relationship between Fosamax and ONJ evaluated?

Causation is supported by the timeline of symptom onset after starting Fosamax (ranging from one day to months), symptom relief upon discontinuation, and recurrence upon rechallenge. However, in clinical trials, the incidence of jaw symptoms was similar between Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.